Latest News and Press Releases
Want to stay updated on the latest news?
-
Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...
-
Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Interleukin-2 - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's...
-
Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has been added to ...
-
Dublin, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease (GvHD) Treatment Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This GvHD treatment...
-
Rockville, MD, Nov. 12, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global Cryoglobulinemic vasculitis market is estimated to reach a...
-
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Immunomodulators - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Immunomodulators...
-
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Graft Versus Host Disease (GvHD) Treatment Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The graft...
-
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Adalimumab (Humira) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...
-
Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Post-Transplant Lymphoproliferative Disorder - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report...
-
Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "Immunosuppressants - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...